

DAFTAR PUSTAKA

- AbuHammad, S. and M Zihlif. 2012. Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. *Genomic*, **101**: 213–220
- Albert J, J Lewis, M Raff, K Roberts, P Walter. 2008. *Molecular Biology of The Cell*. Fifth Edition. Garland Science : Oxford. p : 1017, 1115-1118, 1120.
- Aggarwal BB, Kumar A, Bharti AC. 2003. Anticancer potential of curcumin: preclinical and clinical studies. *Anticancer Res*. **23**(1A):363-98.
- Aggarwal, BB. and Harikumar, KB. 2009. Potential therapeutic effects of curcumin, the antiinflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *J. Biochemistry and Cell Biology*, **41**: 40-59.
- Baehrecke, EH dan H Mehmet . 2003. Nuclear Changes in Dying Cells. In: D Hughes dan H Mehmet (eds). *Cell Proliferation dan Apoptosis*. BIOS Scientific Publisher Limited. Oxford. p: 296.
- Baguley B.C. 2010. Multidrug Resistance Mechanisms in Cancer. *Molecular Biotechnology*. vol.**46** (3) , 308-316.
- Bandyopadhyay, A. L Wang, J Agyin, Y Tang, S Lin, IT Yeh, K De, and LZ Shun. 2010. Doxorubicin in Combination with a Small TGF β Inhibitor: A Potential Novel Therapy for Metastatic Breast Cancer in Mouse Models. *PlosOne* vol.5.
- Banerji, A. J Chakrabarti, AMitra, and A Chatterjee. 2004. Effect of curcumin on gelatinase A (MMP-2) activity in B16F10 melanoma cells. *Cancer Letters*. **211**. 235-242
- Blanco, MA. and Y Kang. 2011. Signaling pathways in breast cancer metastasis -novel insights from functional genomics. *Breast Cancer Research*, **13**. 206.
- Campbell NA, JB Reece, LAUrry, ML Cain, SA Wasserman, PV Minorsky, and RB Jackson. 2014. *Biology, 10th Edition*. San Fransisco: Pearson Education Benjamin Cummings. p : 235.
- Chacon, RD. and MV Costanzo. 2010. Triple-negative Breast Cancer. *Breast Cancer Research*, **12**. 1-9.
- Chiu, TL. and CC Su. 2009. Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF- κ Bp65 expression in breast cancer MDA-MB-231 cells. *International Journal of Molecular Medicine*. **23**: 469-475
- Chou, TC. 2006. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. *Pharmacol Rev* **58**: 621–681.

- Chou, TC. 2010. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. *Cancer Res.* **70**(2). 440-446
- Christofori, G. 2006. New signals from the invasive front. *Nature* **441** : 444–450.
- Čunderlíková, B. V Vasovič, F Sieber, T Furre, E Borgen, J M Nesland and Q Peng. 2011. Hexaminolevulinic acid-mediated photodynamic purging of marrow grafts with murine breast carcinoma. *Bone Marrow Transplantation* **46**, 1118–1127.
- Dent, R. M Trudeau, KI Pritchard, WM Hanna, HK Kahn, CA Sawka, LA Lickley, E Rawlinson, P Sun, and SA Narod. 2007. Triple-negative breast cancer: clinical features and patterns of recurrence. *Clin Cancer Res* **13**(15):4429-4434.
- Deveraux, QL. and JC Reed. 1999. IAP family proteins suppressors of apoptosis. *Genes and Development* **13**. 239–252.
- Donzelli, M. and GF Draetta. 2003. Regulating mammalian checkpoints through Cdc25 inactivation. *EMBO.* **vol.4** (7). 671-677.
- Etienne-Manneville S. and A Hall. 2002. Rho GTPases in cell biology. *Nature* **420**: 629–635.
- Fernández, LP., P Jares, M J Rey, E Campo, and A Cardesa. 1998. Cell cycle regulators and their abnormalities in breast cancer. *J Clin Pathol: Mol Pathol*, **51**:305–309.
- Fukata Y, M Amano, K Kaibuchi. 2001. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. *Trends Pharmacol Sci.* **22**:32-39
- Geiger, DR. and TS Peeper. 2009. Metastasis mechanisms. *Biochimica et Biophysica Acta.* **1796**: 293–308.
- Hazan, RB., GR Philips, RF Qiao, L Norton, and SA Aaronson. 2000. Exogenous Expression of N-Chaderin in Breast Cancer Cells Induces Cell Migration, Invasion, and Metastasis. *The Journal of Cell Biology* **vol.148** (4). 779-790
- Hatcher, H., Planalp, R., Cho, J., Torti, F. M., Torti, S. V. 2008. Curcumin From Ancient Medicine to Current Clinical Trials. *Cellular and Molecular Life Sciences*, **65** (11), 1631-1652.
- Hermawan, A., Fitriyani, A., Junedi, S., dan ikawati, M., 2011. PGV-0 and PGV-1 Increased Apoptosis Induction of Doxorubicin on MCF-7 Breast Cancer Cells. *PHARMACON*, **12**
- Holliday, DL. and V Speirs. 2011. Choosing the right cell line for breast cancer research. *Breast Cancer Research*, **13**:215
- Jamieson, D. and AV Boddy. 2011. Pharmacogenetics of genes across the doxorubicin pathway. *Informa Health Care.* UK
- Junedi, S., A Hermawan, M Ikawati, dan E Meiyanto. 2000. *Prosedur Tetap : Uji Sitotoksik Metode MTT.* CCRC Farmasi. Fakultas Farmasi Universitas Gadjah Mada. Yogyakarta.

- Junge, T. 2016. *Practical Pharmacology for The Surgical Technologist*. Cengage Learning. Boston. p : 80.
- Karp, G. 2008. *Cell and Molecular Biology : concept and experiment*. Fifth Edition. John-Wiley and Sons Inc. Hoboken. p: 654.
- Kaur, P, GM Nagaraja, H Zheng, D Gizachew, M Galukande, S Krishnan, and A Asea. 2012. A mouse model for triple-negative breast cancer-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. *BMC Cancer*, **12**:120.
- Kill, IR., and RGA Faragher. 2000. Senescence, Apoptosis, and Necrosis. In JRW Masters (Ed). *Animal Cell Culture*. Third Edition. Oxford University Press. Oxford. p: 293.
- Kim R, M Emi, K Tanabe, Y Uchida, and K Arihiro. 2006. The Role of Apoptotic or Nonapoptotic Cell Death in Determining Cellular Response to Anticancer Treatment. *The Journal Cancer Surgery EJSO* **32** : 269-277. Elsevier.
- Kleinsmith, LJ. 2006. *Principle of Cancer Biology*. Pearson International Edition. Pearson Education Inc. California. p: 12,36, 135-136.
- Lavrik IN, A Golks, and PH Krammer. 2008. Caspases : pharmacological manipulation of cell death. In AR Marks and US Neil (Eds). *Science in Medicine The JCI Textbook of Molecular Medicine*. Jones and Barlett Pub : Sudbury.
- Lemasters, JJ. 2009. Molecular Mechanisms of Cell Death. In WB Coleman and GJ Tsongalis (Eds). *Molecular Pathology : The Molecular Basis of Human Disease*. Elsevier. London p: 5, 13
- Limtrakul, P. 2007. Curcumin as chemosensitizer. *The Molecular Target and Therapeutic Uses of Curcumin in Health and Diseases*. Edited by : Aggarwal BB, YJ Surh, and S Shishodia. Springer. p : 288.
- Liu, D. and Z Chen. 2013. The Effect of Curcumin on Breast Cancer Cells. *J Breast Cancer***16**(2): 133-137.
- Liu, Y., DA Peterson, H Kimura, and D Schubert. 1997. Mechanism of Cellular 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) Reduction. *Journal of Neurochemistry*. Lippincott-Raven Publisher. Philadelphia.
- MacDonald, F and CHJ Ford. 1997. *Molecular Biology of Cancer*. BIOS Scientific Publisher Ltd. Oxford. p: 5-6.
- Meiyanto, E. 1999. Kurkumin sebagai Obat Kanker: Menelusuri Mekanisme Aksinya”, *Majalah Farmasi Indonesia*, **10**(4).
- Meiyanto, E., Putri, D.D.P., Susidarti, R.A., Murwanti, R., Sardjiman, Fitriyasari, A., et al., 2014. Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. *Asian Pacific journal of cancer prevention APJCP*. **15**: 179–184.
- Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, Aggarwal BB. 2002. Curcumin-induced suppression of cell proliferation correlates with

- down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. *Oncogene* **21**(57):8852-61
- Mukhopadhyay, P. M Rajesh, S Batkai, Y Kashiwaya, G Hasko, L Liaudet, C Szabo, and P Pacher. 2009. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. *Am J Physiol Heart Circ Physiol* **296**: 1466–1483.
- Nagase, H. and JF Woessner. 1999. Matrix metalloproteinase. *J Biol Chem.* **274**. 2491-2494
- Nicotera, P. and G Melino. 2004. Regulation of the apoptosis–necrosis switch. *Oncogene* **23**. 2757–2765.
- Nitiss, J.L., 2009. Targeting DNA topoisomerase II in cancer chemotherapy. *Nature reviews. Cancer*, **9**: 338–350.
- Notarbartolo, M. P Poma, D Perria, L Dusonchet, M Cervello, and N D'Alessandro. 2005. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF- κ B activation levels and in IAP gene expression. *Cancer Lett.* **224**. 53-65.
- Ovcaricek, T. SG Frkovic, E Matos, B Mozina, and S Borstnar. 2011. *Triple negative breast cancer – prognostic factors and survival. Radiol Oncol* **45** (1). 46-52.
- Pardee, AB. 2003. Regulation of The Cell Cycle. *The Cancer Handbook*. (Ed) MH Allison. Nature Publishing Group. p : 13-23.
- Parri, M. dan Chiarugi, P., 2010. Rac and Rho GTPases in cancer cell motility control. *Cell communication and signaling: CCS*, **8**: 23.
- Putri, H. RI Jenie, S Handayani, RF Kastian, and E Meiyanto. 2016. Combination of Potassium Pentagamavunon-0 and Doxorubicin Induces Apoptosis and Cell Cycle Arrest and Inhibits Metastasis in Breast Cancer Cells. *Asian Pac J Cancer Prev*, **17** (5) : 2683-2688.
- Riccardi, C. and I Nicoletti. 2006. Analysis of apoptosis by propidium iodide staining and flow cytometry. *Nature Protocols*. vol. **1**(3). 1458-1461
- Rodriguez, D., CJ Morrison, and CM Overall. 2010. Matrix metalloproteinases: What do they not do? New substrates and biological roles identified by murine models and proteomics. *Biochimica et Biophysica Acta*, **1803** 39–54.
- Sherwood L. 2010. *Human Physiology : from Cells to System*. Seventh Edition. Brook/Cole : Belmont.
- Shishodia, S., Chaturvedi, M. M., Aggarwal, B. B., 2007. Role of Curcumin in Cancer Therapy. *Curr Probl Cancer* **31**(4). 243-305.
- Soane, L., BM Polster, and G Fiskum. 2011. Mitochondrial Mechanisms of Neural Cell Death in Cerebral Ischemia. In JC Reed and DR Green (Eds). *Apoptosis : Physiology and Pathology*. Cambridge University Press. New York. p: 155, 295, 297.

- Solomon, EP., LR Berg, and DW Martin. 2008. *Biology*. Eight Edition. Thomson Brooks/Cole. Belmont. p : 95.
- Stockert, JC., A Blazquez-Castro, M Canete, RW Horobin, and A Villanueva. 2012. MTT assay for cell viability : Intracellular localization of the formazan product is in lipid droplets. *Acta Histochemica***114** 785-796. Elsevier.
- Sun, XD, XE Liu, and DS Huang. 2012. Curcumin induces apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression. *Molecular Medicine Reports***6**. 1267-1270
- Sutejo, IR. 2015. *Potensi Antimetastasis Kombinasi Temulawak (Curcuma xanthorrhiza) Buah Makassar (Brucea javanica) dan Doxorubicin Pada Sel 4T1*. Tesis. Program Studi Bioteknologi, Universitas Gadjah Mada, Yogyakarta.
- Tao, K., M Fang, J Alroy, and GG Sahagian. 2008. Imagable 4T1 Model for The Study of Late Stage Breast Cancer. *BMC Cancer***(8)** 228. BioMed Central.Ltd.
- Tsang, WP, SPY Chau, SK Kong, KP Fung, TT Kwok. 2003. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. *Life Sciences*. **73**. 2047–2058. Elsevier.
- Tunjung, WAS., M Yokoo, Y Hoshino, Y Miyake, A Kadowaki, and E Sato. 2009. Effect of Hyaluronan to Inhibit Caspase Activation in Porcine Granulosa Cells. *Biochemical and Biophysical Research Communication* **382** : 160-164. Elsevier.
- van Leeuwen FN, van DS, HE Kain, RA van der Kammen, and JG Collard . 1999. Rac regulates phosphorylation of the myosin-II heavy chain, actinomyosin disassembly and cell spreading. *Nat Cell Biol* .**1** 242-248.
- Vermes, I. C Haanen, HS Nakken, and C Reutelingsperger. 1995. A novel assay for apoptosis Flow cytometric detection of phosphatidylserineearly apoptotic cells using fluorescein labelledexpression onAnnexin V. *Journal of Immunological Methods*.**184** (199.5). 39-51.
- Wang, S, EA. Konorev, S Kotamraju, J Joseph, S Kalivendi, and B. Kalyanaraman. 2004. Doxorubicin Induces Apoptosis in Normal and Tumor Cells via Distinctly Different Mechanisms. *The Journal Of Biological Chemistry* Vol. **279** (24). 25535–25543.
- Wilken, R., Veena, M., Wang, M., Srivatsan, S., 2011. Kurkumin: A review of anti-cancerproperties and therapeutic activity in head and neck squamous cell carcinoma. *Molecular Cancer*, **10**:12.
- Wright W and CS Duckett. 2008.Reawwkening the Cellular Death Program in Neoplasia Through The Therapeutic Blocade of IAP Function. Science in Medicine The JCI Textbook of Molecular Medicine. Jones and Barlett Pub : Sudbury. P :35.

- Xu, J. Y Chen, and OL Olopade. 2010. MYC and Breast Cancer. *Genes and Cancer* **1**(6). 629–640.
- Yang, L. 2005. Disfunction of the Apoptotic Pathway in Cancer Cell. In M.Sluyser (Ed). *Application of Apoptosis to Cancer Treatment*. Springer. Dordrecht. p : 3, 5.
- Yao, D. C Dai, and S Peng. 2011. Mechanism of the Mesenchymal–Epithelial Transition and Its Relationship with Metastatic Tumor Formation. *Molecular Cancer Research*, **9** : 12.
- Yerlikaya, A. E Okur, and E Ulukaya. 2012. The p-53-independent induction of apoptosis in breast cancer in response to proteasome inhibitor bortezomib. *Tumor Biology*. **33**. 1385–1392
- Zhang, WH. A Poh, AA Fanous, and A Eastman. 2008. DNA damage-induced S phase arrest in human breast cancer dependson Chk1, but G2 arrest can occur independently of Chk1, Chk2or MAPKAPK2. *Cell Cycle* **7** (11). 1668-1677.